Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of August 18th - 24th, 2023.

He highlights the TROPiCS-02 trial of sacituzumab govitecan demonstrating significant overall survival improvement over chemotherapy in patients with pretreated endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer.

He also covers the TBCRC 030 trial which looked at circulating tumour DNA analysis as a predictive biomarker in early-stage triple-negative breast cancer.

In addition, he covers the use of stereotactic body radiotherapy as an effective treatment modality for hepatocellular carcinoma patients with mature follow-up.

Follow Dr Morgan on twitter: @OncoAlert



Follow ecancer on twitter: @ecancer